Up-front immunotherapy is the most cost-effective option for treating newly diagnosed unresectable stage III or IV melanoma with unknown BRAF mutation status, concludes a modeling analysis.
Correlating survival outcomes in patients with advanced prostate cancer with novel hyperpolarized 13C MRI metabolic imaging biomarkers. KRAS c.436G > A p.Ala146Thr ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results